ArticleCJC open2025
Pathophysiological and Prognostic Importance of an ExtraCardiac Comorbidity Burden in Patients with Heart Failure with Preserved Ejection Fraction.
Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.Vascular health and risk management · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracardiac comorbidities are highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF). We investigated the pathophysiological contribution of an extracardiac comorbidity burden to cardiac function, exercise capacity, and prognosis in patients with HFpEF. Methods: A total of 775 patients (372 HFpEF patients and 403 control subjects) underwent exercise echocardiography, with simultaneous expired gas analysis. We separated the previously validated Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score into cardiac, extracardiac, and demographic categories. An Extracardiac burden was defined as an extracardiac domain score ≥ 5 (median value). Results: Compared to control subjects (n = 403) and patients with HFpEF without an extracardiac burden (n = 185), patients with HFpEF with an extracardiac burden (n = 187) had higher natriuretic peptide levels and worse exercise capacity. They also had worse ventilatory efficiency and worse peripheral O Conclusions: An extracardiac comorbidity burden in patients with HFpEF is associated with relevant pathophysiological features characterized by impaired exercise capacity, worse ventilatory efficiency, impaired O
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.